Skip to main content

Table 3 Secondary outcomes

From: High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial

 

Active HFCWO (n = 25)

Sham HFCWO (n = 27)

Comparison between groups p-value

After four treatments

   

   Change in Borg score

-1.5 [-3.5, 0]

n = 24

0 [-2, 0]

n = 26

0.048

   Expectorated sputum, mL

10 [8, 20]

11 [6, 45]

0.44

Change in post-BD FEV1%

predicted

0 [-2, 8]

n = 22

2 [-3, 9]

n = 23

0.69

Length of hospital stay, days

2 [1, 3]

2 [1, 4]

0.75

Respiratory- related acute care at 30 days

   

   Systemic corticosteroids, n (%)

4 (17)

n = 23

2 (8)

n = 24

0.42

Acute care visit (hospitalization or

ED visit), n (%)

4 (17)

n = 23

4 (17)

n = 24

> 0.99

   Either

5 (22)

n = 23

4 (17)

n = 24

0.72

  1. The median [interquartile range] is reported, unless otherwise stated. The number (n) of participants with data is included in the table, if n is less than the number of participants assigned to each treatment group. Missing data were due to difficulty in performing some tests in acutely ill patients (e.g., post-BD spirometry) or non-response (e.g., problems with patient recall or inability to respond). There were five participants lost to follow-up (2 in active HFCWO, 3 in sham HFCWO groups).